277
Participants
Start Date
August 18, 2017
Primary Completion Date
February 8, 2023
Study Completion Date
February 8, 2023
tebotelimab 1 mg
1 mg IV every other week
tebotelimab 3 mg
3 mg IV every other week
tebotelimab 10 mg
10 mg IV every other week
tebotelimab 30 mg
30 mg IV every other week
tebotelimab 120 mg
120 mg IV every other week
tebotelimab 300 mg
300 mg IV every other wee
tebotelimab 400 mg
400 mg IV every other wee
tebotelimab 600 mg
600 mg IV every other week
tebotelimab 800 mg
800 mg IV every other week
tebotelimab 1200 mg
1200 mg IV every other week
margetuximab
15 mg/kg IV every 3 weeks
"Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda EAD, Sofia", Sofia
"Multiprofile Hospital for Active Treatment Serdika EOOD, Sofia", Sofia
St Vincent's Hospital Sydney, Darlinghurst
Calvary Mater Newcastle, Waratah
Southern Medical Day Care Centre, Wollongong
Austin Health Melbourne, Heidelberg
"Complex Oncology Center - Burgas EOOD", Burgas
King Chulalongkorn Memorial Hospital, Bangkok
UPMC Hillman Cancer Center, Pittsburgh
"Communal Nonprofit Enterprise Cherkassy Regional Oncology Dispensary of Cherkassy Regional Council", Cherkassy
University of Pennsylvania, Abramson Cancer Center, Philadelphia
Communal Nonprofit Enterprise Podillia Regional Center of Oncology of Vinnytsia Regional Council, Vinnytsia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Duke University Medical Center, Durham
Hospital Ruber Internacional, Madrid
START Madrid-CIOCC, Hospital HM Sanchinarro, Madrid
Florida Cancer Specialists & Research Institute, Sarasota
Sarah Cannon Research Institute, Nashville
"Municipal Non-Profit Enterprise of Sumy Regional Council Sumy Regional Clinical Oncology Dispensary", Sumy
Cincinnati Children's Hospital Medical Center, Cincinnati
"Communal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council", Dnipro
Maharaj Nakorn Chiang Mai Hospital, Chiang Mai
University of Chicago Medicine, Chicago
Stephenson Cancer Center, The University of Oklahoma, Oklahoma City
"Communal Nonprofit Enterprise Prykarpatsky Clinical Oncological Centre of Ivano-Frankivska Regional Council", Ivano-Frankivsk
The University of Texas M.D. Anderson Cancer Center, Houston
Banner MD Anderson Cancer Center, Gilbert
"Communal Nonprofit Enterprise Central City Clinical Hospital of Uzhhorod City Council, City Oncology Center, State Higher Educational Institution <<Uzhhorod National University>>", Uzhhorod
USC/Norris Comprehensive Cancer Center, Los Angeles
UCLA Hematology & Oncology Clinic, Los Angeles
Songklanagarind Hospital, Songkhla
Hoag Memorial Hospital Presbyterian, Newport Beach
Massachusetts General Hospital and Dana-Farber Cancer Institute, Boston
Prince of Wales Hospital, Shatin
Pratia MCM Kraków, Krakow
BioVirtus Research Site Sp. Z o.o. / Biovirtus Centrum Medyczne, Józefów
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warsaw
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warsaw
Med-Polonia Sp. z o.o., Poznan
Vall d'Hebron Institute of Oncology, Barcelona
Lead Sponsor
MacroGenics
INDUSTRY